Patents by Inventor Yimin Qian

Yimin Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220274955
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 1, 2022
    Inventors: Andrew P. CREW, Yimin QIAN, Hanqing DONG, Jing WANG
  • Patent number: 11427548
    Abstract: The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: August 30, 2022
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian, Kurt Zimmermann, Michael Berlin, Lawrence Snyder
  • Publication number: 20220267305
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 25, 2022
    Inventors: Andrew P. Crew, Hanqing Dong, Keith R. Hornberger, Yimin Qian, Jing Wang
  • Patent number: 11420956
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: August 23, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Publication number: 20220259207
    Abstract: The present disclosure relates to novel compounds that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.
    Type: Application
    Filed: February 2, 2022
    Publication date: August 18, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Yimin Qian, Wei He, Robert Luo, JIE SU, HUI ZHANG, KE LIU, JIE FAN
  • Patent number: 11384063
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: July 12, 2022
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Hanqing Dong, Jing Wang, Yimin Qian
  • Publication number: 20220193072
    Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2? breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 23, 2022
    Inventors: Xin CHEN, Andrew P. CREW, John FLANAGAN, Sheryl Maxine GOUGH, Royal J. HASKELL, III, Marcia Dougan MOORE, Yimin QIAN, Ian Charles Anthony TAYLOR, Jing WANG
  • Patent number: 11352351
    Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 7, 2022
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Meizhong Jin, Andrew P. Crew, Hanqing Dong, Jing Wang, Xin Chen, Yimin Qian
  • Publication number: 20220162163
    Abstract: The description relates to Inhibitors of Apoptosis Proteins (IAPs) binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the IAP E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Application
    Filed: January 5, 2022
    Publication date: May 26, 2022
    Inventors: Michael Berlin, Andrew P. Crew, Hanqing Dong, Yimin Qian
  • Publication number: 20220127279
    Abstract: The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the MDM2 E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Inventors: Andrew P. Crew, Craig M. Crews, Hanqing Dong, Yimin Qian, Jing Wang
  • Patent number: 11312702
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: April 26, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Publication number: 20220112204
    Abstract: The present disclosure relates to novel compounds that inhibit KRAS G120, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Robert Z. LUO
  • Publication number: 20220089570
    Abstract: The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Application
    Filed: September 24, 2021
    Publication date: March 24, 2022
    Inventors: Andrew P. CREW, Craig M. CREWS, Hanqing DONG, Meizhong JIN, Yimin QIAN, Jing WANG
  • Patent number: 11261178
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: March 1, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11220490
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: January 11, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11191741
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 7, 2021
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Lawrence B. Snyder, Jing Wang, Yimin Qian, Michael Berlin
  • Publication number: 20210315856
    Abstract: The present disclosure is based on the surprising and unexpected discovery that a ligand molecule with certain characteristics is able to bind to two protein molecules simultaneously and recruit them to form a transient or stable protein-protein interaction complex. The protein-protein interaction and other cross-domain interactions gained in this process contribute additional stabilization energy to the complex beyond the combination of the binary binding energies, and therefore, largely increase the binding potency of the ligand. Accordingly, the present disclosure provides a Protein-Protein Interaction Inducing Technology (PPIIT), which includes a method to design and identify the tripartite or bifunctional compounds and use such compounds to induce protein-protein interactions in various contexts. The present disclosure also provides a composition for the purpose of inducing protein-protein interactions.
    Type: Application
    Filed: June 24, 2021
    Publication date: October 14, 2021
    Inventors: Andrew P. Crew, Hanging Dong, Brain Hamman, Taavi K. Neklesa, Yimin Qian, Jing Wang, Kurt Zimmermann
  • Publication number: 20210300901
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Application
    Filed: May 26, 2021
    Publication date: September 30, 2021
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Ke LIU
  • Patent number: 11104666
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: August 31, 2021
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Yimin Qian, Hanqing Dong, Jing Wang, Keith R. Hornberger
  • Publication number: 20210221802
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Application
    Filed: June 22, 2020
    Publication date: July 22, 2021
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin Qian, Wei He, Ke Liu